Boost For India’s Generic Pharma Majors
Biocon, Dr Reddy’s and Mankind Pharma stress on development and manufacturing of biological drugs, look to cash in on a growing market.
Biocon, Dr Reddy’s and Mankind Pharma stress on development and manufacturing of biological drugs, look to cash in on a growing market.
Lupin deals in branded and generic formulations, active pharmaceutical ingredients (APIs), and biosimilars.
As per the regulatory filing by the pharmaceutical major, through the acquisition, Sun Pharma aims to facilitate the consolidation of business in Israel.
Established with a clear vision, Akums remains unwavering in its commitment to excel in the pharmaceutical industry.
The company's revenue from operations in the Q2 of FY24, stood at ₹5,038.6 crore, up 21.5% YoY as against ₹4,145.5 crore in the same period last year.
The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor), the company says.
Glenmark Pharma entered into a definitive agreement with Nirma Limited to divest a 75% stake in Glenmark Life Sciences at a price of ₹615/- per share for an aggregate consideration of ₹5,615 crore.
Vicky Ramancha states that healthcare as a business is in a significant growth stage and RNR Healthcare is looking to double its revenues and profitability in the next 2 years
Nine established pharma companies will be selected on the basis of their willingness to carry out research in six priority areas with academic collaboration in government research institutions.
The revenue from operations of the Mumbai-based company stood at ₹11,940.8 crore, up 10.9% as against 10,761.7 crore in the Q1 of FY23.